» Articles » PMID: 31547023

Carbapenem-Resistant Enterobacteriaceae Posing a Dilemma in Effective Healthcare Delivery

Abstract

The emergence and spread of Carbapenem-resistant (CRE) is seriously posing threats in effective healthcare delivery. The aim of this study was to ascertain the emergence of CRE at Chukwuemeka Odumegwu Ojukwu University Teaching Hospital (COOUTH) Awka. Biological samples were collected from 153 consenting patient from 5 clinics in the hospital. The isolates were identified using standard microbiological protocols. Susceptibility to meropenem was done using Kirby-Bauer disc diffusion method on Mueller Hinton Agar. A total of 153 patients were recruited in this study. About one half of those from rural, 63.64% from Sub-urban and 42.27% from urban areas had significant and spp infections. The male: female ratio of the infection was 1:1. Almost as much inpatient as outpatient study participants had the infections. The infections were observed mostly on participants with lower educational status. The unmarried individuals were most infected compared to their married counterparts. infection rate was 50.98%. Of this, 28.21% had CRE infection while the overall prevalence of the CRE in the studied population was 14.38% (22/153). This study shows that CRE is quickly emerging in both community and hospital environments. spp was the most common CRE in this hospital especially . Hospitalization was a strong risk factor in the CRE infections. Rapid and accurate detection is critical for their effective management and control.

Citing Articles

Investigation of in vitro susceptibility and resistance mechanisms to amikacin among diverse carbapenemase-producing Enterobacteriaceae.

Wu X, Li X, Yu J, Fan C, Shen M, Li X BMC Med Genomics. 2024; 17(1):240.

PMID: 39354545 PMC: 11446084. DOI: 10.1186/s12920-024-02016-0.


High prevalence of carbapenem-resistant (CRE) in human samples from Nigeria: A systematic review and meta-analysis.

Irekeola A, Shueb R, Engku Abd Rahman E, Afolabi H, Wada Y, Elmi A Heliyon. 2024; 10(15):e34926.

PMID: 39144932 PMC: 11320313. DOI: 10.1016/j.heliyon.2024.e34926.


Broad-spectrum antibiotic prophylaxis in tumor and infected orthopedic surgery-the prospective-randomized, microbiologist-blinded, stratified, superiority trials: BAPTIST Trials.

Uckay I, Bomberg H, Risch M, Muller D, Betz M, Farshad M Trials. 2024; 25(1):69.

PMID: 38243311 PMC: 10799415. DOI: 10.1186/s13063-023-07605-5.


Molecular characterization of IncFII plasmid carrying in a serovar Typhimurium ST34 clinical isolate in China.

Zeng S, Huang Y, Zhang X, Fu L, Sun Z, Li X mSphere. 2023; 8(6):e0048023.

PMID: 37909767 PMC: 10732066. DOI: 10.1128/msphere.00480-23.


In Vitro Activity of New β-Lactamase Inhibitor Combinations against , , and ESBL-Producing Enterobacteriales Uropathogens.

Razaq L, Uddin F, Ali S, Abbasi S, Sohail M, Yousif N Antibiotics (Basel). 2023; 12(10).

PMID: 37887182 PMC: 10604030. DOI: 10.3390/antibiotics12101481.


References
1.
Basak S, Singh P, Rajurkar M . Multidrug Resistant and Extensively Drug Resistant Bacteria: A Study. J Pathog. 2016; 2016:4065603. PMC: 4749793. DOI: 10.1155/2016/4065603. View

2.
Mohamudha P, Harish B, Parija S . Molecular description of plasmid-mediated AmpC β-lactamases among nosocomial isolates of Escherichia coli & Klebsiella pneumoniae from six different hospitals in India. Indian J Med Res. 2012; 135:114-9. PMC: 3307170. DOI: 10.4103/0971-5916.93433. View

3.
Kang J, Yi J, Ko M, Lee S, Lee J, Kim K . Prevalence and Risk Factors of Carbapenem-resistant Acquisition in an Emergency Intensive Care Unit in a Tertiary Hospital in Korea: a Case-Control Study. J Korean Med Sci. 2019; 34(18):e140. PMC: 6509365. DOI: 10.3346/jkms.2019.34.e140. View

4.
Okoche D, Asiimwe B, Katabazi F, Kato L, Najjuka C . Prevalence and Characterization of Carbapenem-Resistant Enterobacteriaceae Isolated from Mulago National Referral Hospital, Uganda. PLoS One. 2015; 10(8):e0135745. PMC: 4540283. DOI: 10.1371/journal.pone.0135745. View

5.
Pfeifer Y, Cullik A, Witte W . Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens. Int J Med Microbiol. 2010; 300(6):371-9. DOI: 10.1016/j.ijmm.2010.04.005. View